PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 28 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Evaluated for efficacy in a multi-center, randomized, double-blind trial comparing different dosage forms [PMID:19821105]
Reduced liver damage in mice by inhibiting CYP7A1 expression and inducing autophagy [PMID:41079251]
Aqueous extract inhibits ESCC by targeting the PI3K/AKT/mTOR pathway [PMID:41966342]; oridonin combined with cisplatin synergistically inhibits cell proliferation, migration, and invasion [PMID:40250733]
Ponicidin was identified as a compound that suppresses HCC cell proliferation and migration by modulating CHPF2 [PMID:40107635]
Safety & adverse effects
Drug interactions
Evidence summary
PubMed sources
- 1.PMID: 29959312 (2018) — Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. · Nature communications
- 2.PMID: 40107635 (2025) — CHPF2 as a novel biomarker and ponicidin as a potential therapeutic agent in hepatocellular carcinoma. · Pharmacological research
- 3.PMID: 26389430 (2002) — Oridonin alleviates SiNPs-induced pulmonary fibrosis by inhibiting pyroptosis via IRE1α-XBP1s-NLRP3 pathway. · International immunopharmacology
- 4.PMID: 26389352 (2002) — Cytotoxic ent-Kaurane Diterpenoids from Rabdosia Rubescens. · Chemistry & biodiversity
- 5.PMID: 35401233 (2022) — Isodon rubescens (Hemls.) Hara.: A Comprehensive Review on Traditional Uses, Phytochemistry, and Pharmacological Activities.